Available Trials

Bladder |  BMT |  Brain |  Carcinoid |  Breast |  Cholangiocarcinoma |  Colorectal |  Colorectal/GI |  Endocrine |  Gastric/Gastroesophageal |  Genitourinary |  Head/Neck |  Hematology |  Hepatocellular |  Leukemia |  Lung - Non-Small Cell Lung |  Lymphoma |  Melanoma |  Multiple Myeloma |  Pancreas |  Prostate |  Renal |  Small Cell Lung |  Supportive Care |

Bladder

  • CALGB 90601
    A Randomized Double-Blinded Phase III Study Comparing Gemcitabine, Cisplatin and Bevacizumab to Gemcitabine, Cisplatin and Placebo in Patients with Advanced Transitional Cell Carcinoma
    Available at: Arlington Heights,  Niles

BMT

  • BMT CTN 0702
    A Trial of Single Autologous Transplant With or Without Consolidation Therapy Versus Tandem Autologous Transplant with Lenalidomide Maintenance for Patients with Mulitple Myeloma
    Available at: Niles

Brain

  • ECOG 3F05
    Phase III Study of Radiation Therapy with or without Temozolomide for Symptomatic or Progressive Low-Grade Gliomas
    Available at: Niles

Carcinoid

  • ECOG S0518
    Phase III Prospective Randomized Comparison of Depot Octreotide Plus Interferon Alpha Versus Depot Octreotide Plus Bevacizumab (NSC #704865) in Advanced, Poor Prognosis Carcinoid Patients
    Available at: Arlington Heights,  Niles

Breast

  • S1007
    A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients with 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer with Recurrence Score of 25 or Less
    Available at: Arlington Heights,  Niles
  • NSABP B-43
    A Phase III Clinical Trial Comparing Trastuzumab Given Concurrently with Radiation Therapy and Radiation Therapy Alone for Women with HER2-Positive Ductal Carcinoma in Situ resected by Lumpectomy
    Available at: Arlington Heights,  Niles
  • ECOG N063D
    ALTTO: Adjuvant Lapatinib and/or Trastuzumab Treatment Optimisation Study A randomised, multi-centre, open-label, phase III study of adjuvant lapatinib, trastuzumab, their sequence and their combination in patients with HER2/ErbB2 positive primary breast cancer
    Available at: Niles
  • USO 09097
    A RANDOMIZED, OPEN-LABEL STUDY OF LAPATINIB PLUS TRASTUZUMAB VERSUS TRASTUZUMAB AS CONTINUED HER2 SUPRRESSION THERAPY AFTER COMPLETION OF FIRST – OR SECOND-LINE TRASTUZUMAB PLUS CHEMOTHERAPY IN PATIENTS WITH HER2-POSITIVE METASTATIC BREAST CANCER
    Available at: Arlington Heights,  Niles
  • E2108
    RANDOMIZED PHASE III TRIAL OF THE VALUE OF EARLY LOCAL THERAPY FOR THE INTACT PRIMARY TUMOR IN PATIENTS WITH METASTATIC BREAST CANCER
    Available at: Arlington Heights,  Niles

Cholangiocarcinoma

  • SWOG S0809
    A PHASE II TRIAL OF ADJUVANT CAPECITABINE/GEMCITABINE CHEMOTHERAPY FOLLOWED BY CONCURRENT CAPECITABINE AND RADIOTHERAPY IN EXTRAHEPATIC CHOLANGIOCARCINOMA (EHCC)
    Available at: Arlington Heights,  Niles

Colorectal

  • ECOG 7208
    A Randomized Phase II Study of Irinotecan and Cetuximab With or Without the Anti-Angiogenic Antibody, Ramucirumab (IMC-1121B), in Advanced, K-RAS Wild-Type Colorectal Cancer Following Progression on Bevacizumab-Containing Chemotherapy
    Available at: Arlington Heights,  Niles
  • CALGB 80702
    A Phase III Trial of 6 Versus 12 Treatments of Adjuvant FOLFOX Plus Celecoxib or Placebo for Patients with Resected Stage III Colon Cancer
    Available at: Arlington Heights,  Niles
  • NU0714  
    A RANDOMIZED PHASE II STUDY OF DUAL EPIDERMAL GROWTH FACTOR RECEPTOR INHIBITION WITH ERLOTINIB AND PANITUMUMAB WITH OR WITHOUT IRINOTECAN AS SECOND LINE THERAPY IN PATIENTS WITH METASTATIC COLORECTAL CANCER
    Available at: Arlington Heights

Colorectal/GI

  • ECOG 3205
    Phase II Trial of Cetuximab Plus Cisplatin, 5-Fluorouracil and Radiation in Immunocompetent Patients with Anal Carcinoma
    Available at: Arlington Heights,  Niles

Endocrine

  • ECOG S0518
    Phase III Prospective Randomized Comparison of Depot Octreotide Plus Interferon Alpha Versus Depot Octreotide Plus Bevacizumab (NSC #704865) in Advanced, Poor Prognosis Carcinoid Patients
    Available at: Arlington Heights,  Niles

Gastric/Gastroesophageal

  • RTOG 1010
    A PHASE III TRIAL EVALUATING THE ADDITION OF TRASTUZUMAB TO TRIMODALITY TREATMENT OF HER-2 OVEREXPRESSING ADENOCARCINOMA
    Available at: Arlington Heights
  • ECOG 2208
    Randomized Phase II Study of Paclitaxel With or Without the Anti-IGF-IR mAb Cixutumumab (IMC-A12) as Second Line Treatment for Patients with Metastatic Esophageal or GE Junction Cancer
    Available at: Arlington Heights,  Niles

Genitourinary

  • CALGB 90601
    A Randomized Double-Blinded Phase III Study Comparing Gemcitabine, Cisplatin and Bevacizumab to Gemcitabine, Cisplatin and Placebo in Patients with Advanced Transitional Cell Carcinoma
    Available at: Arlington Heights,  Niles

Head/Neck

  • RTOG 1016
    A PHASE III TRIAL OF RADIOTHERAPY PLUS CETUXIMAB VS CHEMORADIOTHERAPY IN HPV-ASSOCIATED OROPHARYNX CANCER
    Available at: Arlington Heights
  • ECOG 1305
    A Phase III Randomized Trial of Chemotherapy With or Without Bevacizumab in Patients with Recurrent or Metastatic Head and Neck Cancer
    Available at: Arlington Heights,  Niles

Hematology

  • ECOG 2905
    Randomized Phase III Trial Comparing the Frequency of Major Erythroid Response (MER) to Treatment with Lenalomide (Revlimid) Alone and in Combination with Epoetin Alfa (Procrit) in Subjects with Low or Intermediate-1 Risk MDS and Symptomatic Anemia
    Available at: Niles

Hepatocellular

  • CALGB 80802
    Phase III Randomized Study of Sorafenib Plus Doxorubicin Versus Sorafenib in Patients with Advanced Hepatocellular Carcinoma (HCC)
    Available at: Arlington Heights,  Niles

Leukemia

  • ECOG 2906
    Phase III Randomized Trial of Clofarabine as Induction and Post-Remission Therapy vs Standard Daunorubicin & Cytarabine Induction and Intermediate Dose Cytarabine Post-Remission Therapy, Followed By Decitabine Maintenance vs Observation in Newly-Diagnosed Acute Myeloid Leukemia in Older Adults (Age >60)
    Available at: Niles
  • ECOG C10404
    A Genetic Risk-Stratified, Randomized Phase II Study of Four Fludarabine/Antibody Combinations For Patients with Symptomatic, Previously Untreated Chronic Lymphocytic Leukemia
    Available at: Arlington Heights,  Niles
  • ECOG C10603
    A Phase III Randomized, Double-Blind Study of Induction (Daunorubicin/Cytarabine) and Consolidation (High-Dose Cytarabine) Chemotherapy + Midostaurin (PKC412) (IND # 101261) or Placebo in Newly Diagnosed Patients < 60 Years of Age with FLT3 Mutated Acute Myeloid Leukemia (AML)
    Available at: Arlington Heights,  Niles
  • ECOG 2903
    Phase II Trial of Pentostatin, Cyclophosphamide and Rituximab (PCR) Followed by Campath-1H For Previously Treated Relapsed or Refractory Patients With Chronic Lymphocytic Leukemia
    Available at: Arlington Heights,  Niles

Lung - Non-Small Cell Lung

  • PrECOG 0502
    An Open-Label, Randomized, Phase IIIb Trial of Evaluating the Efficacy and Safety of Standard of Care +/- Continuous Bevacizumab Treatment Beyond Progression of Disease in Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer After First-Line Treatment with Bevacizumab Plus a Platinum Doublet-Containing Chemotherapy
    Available at: Niles
  • USO 11075
    A PHASE II STUDY OF INTRAVENOUS ADMINISTRATION OF REOLYSIN IN COMBINATION WITH PACLITAXEL AND CARBOPLATIN IN PATIENTS WITH SQUAMOUS CELL CARCINOMA OF THE LUNG
    Available at: Arlington Heights,  Niles
  • ECOG 6508
    A Phase II Study of L-BLP25 and Bevacizumab in Unresectable Stage IIIA and Stage IIIB Non-Squamous Non-Small Cell Lung Cancer After Definitive Chemoradaiation
    Available at: Arlington Heights,  Niles
  • ECOG 5508
    Randomized Phase III Study of Maintenance Therapy with Bevacizumab, Pemetrexed, or a Combination of Bevacizumab and Pemetrexed Following Carboplatin, Paclitaxel and Bevacizumab for Advanced Non-Squamous NSCLC
    Available at: Arlington Heights,  Niles
  • ECOG 1505
    A Phase III Randomized Trial of Adjuvant Chemotherapy With or Without Bevacizumab for Patients With Completely Resected Stage IB (> 4 cm) - IIIA Non-Small Cell Lung Cancer
    Available at: Arlington Heights,  Niles

Lymphoma

  • E4208
    A 3 Arm Randomized Phase II Trial of Benamustine-Rituximab (BR) Followed By Rituximab vs Bortezomid-BR (BVR) Followed By Rituximab vs BR Followed By Lenalidomide/Rituximab in High Risk Follicular Lymphoma
    Available at: Niles
  • CALGB 50303
    Phase III Randomized Study of R-CHOP versus Dose-Adjusted EPOCH-R with Molecular Profiling in Untreated De Novo Diffuse Large B-Cell Lymphomas
    Available at: Arlington Heights,  Niles

Melanoma

  • ECOG 1609
    A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy Versus High-Dose Interferon a-2b for Resected High-Risk Melanoma
    Available at: Niles
  • ECOG 1608
    A Phase II Trial of GM-CSF Protein Plus Ipilimumab in Patients with Advanced Melanoma
    Available at: Arlington Heights,  Niles

Multiple Myeloma

  • INDEPENDENT STUDY
    A PHASE III, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, MULTICENTER CLINICAL TRIAL TO STUDY THE SAFETY, TOLERABILITY, EFFICACY, AND IMMUNOGENICITY OF V212/HEAT-TREATED VARICELLA-ZOSTER VIRUS (VZV) VACCINE IN RECIPIENTS OF AUTOLOGOUS HEMATOPOIETIC CELL TRANSPLANTS
    Available at: Niles
  • USON 08209
    A PHASE III RANDOMIZED STUDY TO ASSESS THE EFFICACY AND SAFETY OF PERIFOSINE ADDED TO THE COMBINATION OF BORTEZOMIB AND DEXAMETHASONE IN MULTIPLE MYELOMA PATIENTS PREVIOUSLY TREATED WITH BORTEZOMIB
    Available at: Arlington Heights,  Niles

Pancreas

  • CALGB 80701
    RANDOMIZED PHASE II STUDY OF EVEROLIMUS ALONE VERSUS EVEROLIMUS PLUS BEVACIZUMAB IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC PANCREATIC NEUROENDOCRINE TUMORS
    Available at: Arlington Heights,  Niles
  • RECAP TRIAL
    A RANDOMIZED PHASE II STUDY OF RUXOLITINIB EFFICACY AND SAFETY IN COMBINATION WITH CAPECITABINE FOR SUBJECTS WITH RECURRENT OR REFRACTORY METASTATIC PANCREATIC CANCER
    Available at: Arlington Heights
  • NLG-0405
    A PHASE III STUDY OF CHEMOTHERAPY AND CHEMORADIOTHERAPY WITH OR WITHOUT HYPERACUTE-PANCREAS IMMUNOTHERAPY IN SUBJECTS WITH SURGICALLY RESECTED PANCREATIC CANCER
    Available at: Arlington Heights
  • CA046/USO 05129
    A RANDOMIZED PHASE III STUDY OF WEEKLY ABI-007 PLUS GEMCITABINE VS GEMCITABINE ALONE IN PATIENTS WITH METASTATIC ADENOCARCINOMA OF THE PANCREAS
    Available at: Arlington Heights,  Niles
  • RTOG 0848
    A PHASE III TRIAL EVALUATING BOTH ERLOTINIB AND CHEMORADIATION AS ADJUVANT TREATMENT FOR PATIENTS WITH RESECTED HEAD OF PANCREAS ADENOCARCINOMA
    Available at: Arlington Heights

Prostate

  • ECOG 1809
    A RANDOMIZED PHASE II TRIAL OF DOCETAXEL WITH OR WITHOUT PSATRICOM VACCINE IN PATIENTS WITH CASTRATE RESISTANT METASTATIC PROSTATE CANCER
    Available at: Arlington Heights,  Niles
  • CALGB 90601
    A Randomized Double-Blinded Phase III Study Comparing Gemcitabine, Cisplatin and Bevacizumab to Gemcitabine, Cisplatin and Placebo in Patients with Advanced Transitional Cell Carcinoma
    Available at: Arlington Heights,  Niles
  • ECOG 3805
    CHAARTED: ChemoHormonal Therapy versus Androgen Ablation Randomized Trial for Extensive Disease in Prostate Cancer
    Available at: Arlington Heights,  Niles

Renal

  • CALGB 90601
    A Randomized Double-Blinded Phase III Study Comparing Gemcitabine, Cisplatin and Bevacizumab to Gemcitabine, Cisplatin and Placebo in Patients with Advanced Transitional Cell Carcinoma
    Available at: Arlington Heights,  Niles
  • ECOG 1808
    A RANDOMIZED PHASE II TRIAL OF SUNITINIB/GEMCITABINE OR SUNITINIB IN ADVANCED RENAL CELL CARCINOMA WITH SARCOMATOID FEATURES
    Available at: Arlington Heights,  Niles

Small Cell Lung

Supportive Care

  • Merck V212-011
    A Phase III Randomized, Placebo-Controlled, Clinical Trial to Study the Safety and Efficacy of V212 in Adult Patients with Solid Tumor or Hematologic Malignancy
    Available at: Niles